This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ardelyx (ARDX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA
by Zacks Equity Research
The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -6.25% and 498.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ardelyx (ARDX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Ardelyx (ARDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.
Ardelyx (ARDX) Stock Jumps 6.8%: Will It Continue to Soar?
by Zacks Equity Research
Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -23.08% and -3.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Ardelyx (ARDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Ardelyx Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Ardelyx
Ardelyx (ARDX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Momentum Investors Will Love Ardelyx (ARDX)
by Zacks Equity Research
Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Ardelyx (ARDX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ironwood Amends Linzess Agreement with AstraZeneca in China
by Zacks Equity Research
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment
by Zacks Equity Research
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Ardelyx (ARDX) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study
by Zacks Equity Research
Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.
Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
by Ekta Bagri
Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.
Ardelyx (ARDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -5.13% and -97.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.